NCT05841277

A Study of LY3819469 in Participants With Impaired and Normal Renal Function

Pharmacokinetics of LY3819469 Following Subcutaneous Dose in Participants With Renal Impairment Compared With Participants With Normal Renal Function

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess the amount of study drug (LY3819469) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3819469 will also be evaluated in these participants. The study will last up to 17 weeks including screening period.

Conditions

• Renal Insufficiency
• Healthy

Interventions

Type	Name	Description
DRUG	LY3819469	Administered SC.

Timeline

• Start date: 2023-04-25
• Primary completion: 2024-01-09
• Completion: 2024-01-09
• First posted: 2023-05-03
• Last updated: 2024-03-29

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study